Medicenna Brief: Reporting "Significant" Survival Benefit in Patients With Recurrent Glioblastoma Following Treatment With Bizaxofusp When Compared to a "Matched External Control Arm"
Medicenna Brief: Reporting "Significant" Survival Benefit in Patients With Recurrent Glioblastoma Following Treatment With Bizaxofusp When Compared to a "Matched External Control Arm"
醫藥納簡介：用Bizaxofusp治療復發性膠母細胞瘤的病人報告說，與“匹配的外部對照組”相比，存活率“顯著提高”
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊